Six Important Updates for Colorectal Cancer Awareness Month

Colorectal Cancer Awareness Month is celebrated in March.

Compliance aims to increase awareness of the prevalence of the disease, its symptoms, and the key role screening plays in reducing the incidence and mortality of colorectal cancer.

Colorectal cancer is the second leading cause of cancer death in the United States.

According to the American Cancer Society, an estimated 104,270 people in the United States will be diagnosed with malignancy this year, and 45,230 will die from it.

In conjunction with Colorectal Cancer Awareness Month, Healio and HemOnc today present the following important updates in processing.

• Long-term regular use of aspirin before diagnosis appears to be associated with lower mortality specific to colorectal cancer, according to the results of an observational study published in Journal of the National Cancer Institute. Read more.
• The combination of panitumumab (Vectibix, Amgen), ipilimumab (Yervoy, Bristol Myers Squibb) and nivolumab (Opdivo, Bristol Myers Squibb) induced responses in patients with metastatic colorectal cancer, according to the results of the phase 2 study. Read more.
• A planned study will evaluate CYAD-101 (Celyad Oncology) – an experimental unmodified allogeneic CAR T cell allogeneic therapy – in combination with anti-PD-1 therapy pembrolizumab (Keytruda, Merck) for the treatment of late stage metastatic colorectal cancer. Read more.
• DNA analysis of circulating tumors surpassed an established biomarker for predicting the risk of colorectal cancer recurrence after surgery. Read more.
• Treatment disparities mediated about one-third of the OS differences seen between white and black patients with stage IV colorectal cancer. Read more.
• Pembrolizumab monotherapy has demonstrated superior PFS and PFS2 compared to standard chemotherapy in patients with repair-deficient high microsatellite instability / mismatch metastatic colorectal cancer. Read more.